COVID-19 Vaccine, Is it Safe?
The U.S. vaccine safety system ensures that all vaccines are as safe as possible. To learn how federal partners are working together to ensure the safety of COVID-19 vaccines click here.
COVID-19 Vaccine Recommendations
COVID-19 Vaccine Emergency Use Authorizations
COVID-19 Vaccine Adverse Effects Reporting
VAERS – Vaccine Adverse Event Reporting System
The Vaccine Adverse Effects Reporting System is co-managed by the FDA and CDC to detect rare, unusual or new adverse effects from vaccines. It’s a passive reporting system, relying on individuals to report adverse effects they experience from vaccines.
To learn more please go to www.vaers.hhs.gov
V-safe is a smartphone-based tool (No App required) that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through v-safe, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you and get more information. And v-safe will remind you to get your second COVID-19 vaccine dose if you need one.Your participation in CDC’s v–safe makes a difference — it helps keep COVID-19 vaccines safe. To learn, please go to:
COVID-19 Vaccine Distribution
COVID-19 Vaccine Distribution Tentatively Begins the Week of December 14, 2020
Initial Priority Groups to Receive the Vaccine
It should be noted that all people are assumed susceptible to the virus. Initial populations prioritized for COVID-19 vaccination will be the following based on federal guidance and pending ACIP recommendations, all phases subject to change based on ACIP guidance:
- Health Care Personnel & Residents from Long Term Care Facilities.
- Essential frontline workers including first responders.
- Those with high risk medical conditions and adults over 65 years of age.
Phased Approach to COVID-19 Vaccinations
The Vaccination Campaign will be a phased approach per CDC guidance. There will be a limited supply of COVID-19 vaccines in December 2020, but supply will continually increase in the weeks and months that follow.
The long-term goal
The goal is for everyone to be able to easily get a COVID-19 vaccination as soon as large quantities are available. The plan is to have several thousand vaccination providers available, including doctors’ offices, retail pharmacies, hospitals, and federally qualified health centers.
The Vaccine Manufacturer Selection and Distribution Process
Learn about how the federal government began investing in select vaccine manufacturers to help them increase their ability to quickly make and distribute a large amount of COVID-19 vaccine at hhs.gov.
COVID-19 Phase 1 Vaccine Distribution
Phase 1 of distribution is when there is limited/scarce supply of COVID-19 vaccine doses available. Focus initial efforts on reaching critical populations. Ensure vaccination locations selected can reach populations, manage cold chain requirements, and meet reporting requirements for vaccine supply and uptake.